My main research focus has been applying venom peptide pharmacology to pain pathway characterisation. This approach has led to the identification of novel pain mechanisms underlying the development of chemotherapy-induced pain, ciguatera, and burn-induced pain. In an addition, I have identified and characterised over 20 novel bioactive peptides, which includes a novel class of Nav1.7 inhibitors that is currently undergoing pre-clinical development as analgesics, and a novel class of stinging nettle toxins that act on a previously unidentified Nav1.7 interacting protein named TMEM233.

I am interested in ion channels in health and disease. Improved technologies for genetic screening is revealing an expanding catalogue of genetic variants to ion channels that give rise neurological disorders, such as epilespy syndromes, autism spectrum disorder and other neurodevelopmental disorders. My main research focus is on neurotransmitter-activated receptor ion channels that are found at neuronal synapses. These include GABA-A, glycine and glutamate (NMDA) receptors. I also work on other ion channesl such as voltage-gated sodium channels and synaptic receptors expressed in invertebrate nervous systems.

I am an expert at recording single ion channel, synaptic and conventional whole-cell currents for functional and pharmacological analyisis.

I collaborate with biophysicists, molecular biologists, geneticists, electrophysiologists and clinicians that specialise in genetic neurological disorders. I have active projects in collaboration with research groups in Australia, USA and Europe.

Dr Hana Starobova is a pharmacist and NHMRC research fellow at the Sensory Neuropharmacology Group at the University of Queensland (UQ). She works under the mentorship of Prof. Vetter, and as an early career researcher, she is working toward an independent research career as a group leader. She obtained her PhD in 2020 from the Institute for Molecular Bioscience, UQ, and continued here to conduct studies as a Children Hospital Foundation Fellow (2021-2023) in the areas of cancer therapy-induced adverse and late effects with the main focus on neuropathies. Over the past four years, she has developed a research program focusing on the understanding of cancer therapy-induced adverse and late effects with a special interest in children, and established innovative transcriptomic and microscopy pipelines, in vitro assays, adult and juvenile models of adverse and late effects following mono- and combination chemotherapy and radiotherapy, assays for the assessment of adverse effects including cognition and neuropathies, as well as cancer models. Knowledge impact arising from her research program has been disseminated in 18 peer-reviewed publications, having together attracted >1,100 citations (h-index 15, i10-index 18, Google Scholar, May 2024).